BofA analyst Tazeen Ahmad raised the firm’s price target on Incyte (INCY) to $118 from $114 and keeps a Buy rating on the shares. Updated INCA033989 data in second-line myelofibrosis presented at the ASH meeting reinforces the drug’s potential differentiated profile, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte price target raised to $92 from $86 at Morgan Stanley
- Galecto price target raised to $36 from $32 at Guggenheim
- Incyte’s Mutant CALR Antibody Shows Promise but Faces Uncertainties: Hold Rating Issued
- Incyte’s INCA033989: Promising Myelofibrosis Treatment Drives Buy Rating
- Incyte upgraded to Outperform from Neutral at Mizuho